Drug Profile
Mesodermal progenitor cell therapy - Celixir
Alternative Names: Myocardion; PML cell therapy - CelixirLatest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Celixir
- Class Heart failure therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Heart failure
Most Recent Events
- 28 Feb 2023 Mesodermal progenitor cell therapy is still in preclinical trials for Heart failure in UK (Celixir pipeline, February 2023)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Heart-failure in United Kingdom (Parenteral)
- 13 Jun 2017 Celixir plans phase II trials for mild to moderate Heart failure in Europe (Celixir pipeline, June 2017)